Among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, and low HDL and LDL cholesterol levels, the incidence of cardiovascular events was not lower among those who received pemafibrate than among those who received placebo, although pemafibrate lowered triglyceride, VLDL cholesterol, remnant cholesterol, and apolipoprotein C-III levels. (Funded by the Kowa Research Institute; PROMINENT ClinicalTrials.gov number, NCT03071692.).
The PROMINENT trial, published in NEJM, found that the triglyceride-lowering drug pemafibrate did not reduce cardiovascular events in patients with type 2 diabetes. This has significant implications for the management of dyslipidemia in this patient group and has been a subject of ongoing expert analysis.
Pradhan et al. (2022) studied this question.